Geographies in Depth

Just how deadly is malaria?

Mark Jones
Head of Digital Content, The World Economic Forum
Share:
Our Impact
What's the World Economic Forum doing to accelerate action on Geographies in Depth?
The Big Picture
Explore and monitor how Africa is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

Future of Global Health and Healthcare

The world’s first malaria vaccine has been approved by the European Medicines Agency. It’s called Mosquirix and is the result of a partnership between pharmaceuticals giant GlaxoSmithKline (GSK) and the PATH Malaria Vaccine Initiative, with support from the Bill & Melinda Gates Foundation, that started in 2001 and builds on GSK research going back 30 years.

Trials of Mosquirix have involved more than 16,000 young children, 13 African research centres and eight African nations. Cases among infants (from 6-12 weeks) fell by more than a quarter after three doses. Cases among children aged 5-7 months fell by nearly a half. The vaccine will now be reviewed by the World Health Organisation, which has promised to make a decision by the end of the year.

GSK will make no profit from Mosquirix and says it will price the vaccine at cost plus 5%, a margin it will reinvest in malaria and other tropical-disease research.

Malaria infects around 200 million people a year, the vast majority of them in sub-Saharan Africa.

malariadeaths

Malaria is transmitted by the biting of mosquitoes, and the symptoms usually begin 10-15 days later. In severe cases it causes seizures, coma and death. More than 80% of malaria fatalities are of children under five.

The lack of a vaccine hitherto has made mosquitoes the deadliest animals on the face of the earth.

animalkillers

Have you seen?
How to win the fight against malaria
How can the Asia-Pacific region eliminate malaria by 2030?

Author: Mark Jones is Commissioning Editor for the World Economic Forum.
Image: A young girl with malaria rests in the inpatient ward of the Malualkon Primary Health Care Center in Malualkon, in the South Sudanese state of Northern Bahr el Ghazal, June 1, 2012. REUTERS/Adriane Ohanesian 
Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

How MENA’s biggest actors can help the region’s suppliers and SMEs to decarbonize

Akram Alami and Kelsey Goodman

May 27, 2024

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum